Literature DB >> 26239102

Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations.

Nemanja Rodić1, John Zampella2, Reema Sharma1, Kathleen H Burns1,3,4, Janis M Taube1,2,3.   

Abstract

Decreased hydroxymethylated cytosine (5-hydroxymethycytosine, 5-hmC) is reported to correlate with melanocyte dysplasia. The purpose of this study was to assess the diagnostic utility of this observation. 5-hmC immunohistochemistry was performed on tissue microarrays containing 171-melanocytic lesions from two different institutions. An immunohistochemical staining score representing the percentage and intensity of nuclear staining was assigned. The performance characteristics of 5-hmC immunohistochemistry for discriminating between a nevus and melanoma were determined. Additional cases of melanoma arising in a nevus (n = 8), nodal nevi (n = 5) and melanoma micrometastases to a lymph node (n = 6) were also assessed. Pronounced 5-hmC loss was observed in melanomas when compared with nevi (mean ± standard deviation = 6.71 ± 11.78 and 55.19 ± 23.66, respectively, p < 0.0001). While the mean immunohistochemical staining score values for melanocytic nevi and melanoma were distinct, there was considerable variability in immunohistochemical staining score within a single diagnostic category. The sensitivity and specificity of this assay for nevus vs. melanoma is 92.74 and 97.78%, respectively. Distinct biphasic staining patterns were observed in cases of melanoma arising in association with a nevus. Relative changes of 5-hmC expression within a single lesion may be more informative than absolute values when using 5-hmC as a diagnostic adjunct.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  5-hydroxymethylcytosine; dermatopathology; epigenetics; melanoma; nevus

Mesh:

Substances:

Year:  2015        PMID: 26239102      PMCID: PMC4715679          DOI: 10.1111/cup.12564

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  26 in total

1.  TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine.

Authors:  Haikuo Zhang; Xin Zhang; Erin Clark; Michelle Mulcahey; Stephen Huang; Yujiang Geno Shi
Journal:  Cell Res       Date:  2010-11-16       Impact factor: 25.617

2.  Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors.

Authors:  Theo F J Kraus; Daniel Globisch; Mirko Wagner; Sabina Eigenbrod; David Widmann; Martin Münzel; Markus Müller; Toni Pfaffeneder; Benjamin Hackner; Wolfgang Feiden; Ulrich Schüller; Thomas Carell; Hans A Kretzschmar
Journal:  Int J Cancer       Date:  2012-03-02       Impact factor: 7.396

3.  Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma.

Authors:  Thilo Gambichler; Michael Sand; Marina Skrygan
Journal:  Melanoma Res       Date:  2013-06       Impact factor: 3.599

Review 4.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

5.  Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

Authors:  Thomas Botton; Iwei Yeh; Tyrrell Nelson; Swapna S Vemula; Alyssa Sparatta; Maria C Garrido; Maryline Allegra; Stephane Rocchi; Philippe Bahadoran; Timothy H McCalmont; Philip E LeBoit; Elizabeth A Burton; Gideon Bollag; Robert Ballotti; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2013-08-19       Impact factor: 4.693

6.  Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients.

Authors:  Qi Yang; Kexia Wu; Meiju Ji; Weilin Jin; Nongyue He; Bingyin Shi; Peng Hou
Journal:  J Biomed Nanotechnol       Date:  2013-09       Impact factor: 4.099

7.  Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.

Authors:  Klaus G Griewank; Henrike Westekemper; Rajmohan Murali; Monika Mach; Bastian Schilling; Thomas Wiesner; Tobias Schimming; Elisabeth Livingstone; Antje Sucker; Florian Grabellus; Claudia Metz; Daniela Süsskind; Uwe Hillen; Michael R Speicher; Scott E Woodman; Klaus-Peter Steuhl; Dirk Schadendorf
Journal:  Clin Cancer Res       Date:  2013-04-30       Impact factor: 12.531

8.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification.

Authors:  Shinsuke Ito; Ana C D'Alessio; Olena V Taranova; Kwonho Hong; Lawrence C Sowers; Yi Zhang
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

9.  Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.

Authors:  Christine Guo Lian; Yufei Xu; Craig Ceol; Feizhen Wu; Allison Larson; Karen Dresser; Wenqi Xu; Li Tan; Yeguang Hu; Qian Zhan; Chung-Wei Lee; Di Hu; Bill Q Lian; Sonja Kleffel; Yijun Yang; James Neiswender; Abraham J Khorasani; Rui Fang; Cecilia Lezcano; Lyn M Duncan; Richard A Scolyer; John F Thompson; Hojabr Kakavand; Yariv Houvras; Leonard I Zon; Martin C Mihm; Ursula B Kaiser; Tobias Schatton; Bruce A Woda; George F Murphy; Yujiang G Shi
Journal:  Cell       Date:  2012-09-14       Impact factor: 66.850

10.  Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.

Authors:  Maria Colombino; Amelia Lissia; Mariaelena Capone; Vincenzo De Giorgi; Daniela Massi; Ignazio Stanganelli; Ester Fonsatti; Michele Maio; Gerardo Botti; Corrado Caracò; Nicola Mozzillo; Paolo A Ascierto; Antonio Cossu; Giuseppe Palmieri
Journal:  J Transl Med       Date:  2013-08-29       Impact factor: 5.531

View more
  7 in total

Review 1.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

2.  5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma.

Authors:  Gerald Saldanha; Kushal Joshi; Kathryn Lawes; Mark Bamford; Farhaan Moosa; Kah Wee Teo; J Howard Pringle
Journal:  Mod Pathol       Date:  2016-10-07       Impact factor: 7.842

3.  Loss of the epigenetic mark, 5-Hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma.

Authors:  Jonathan J Lee; Martin Cook; Martin C Mihm; Shuyun Xu; Qian Zhan; Thomas J Wang; George F Murphy; Christine G Lian
Journal:  Oncotarget       Date:  2015-11-10

Review 4.  Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities.

Authors:  Goran Micevic; Nicholas Theodosakis; Marcus Bosenberg
Journal:  Clin Epigenetics       Date:  2017-04-04       Impact factor: 6.551

5.  Proteomics and melanoma: a current perspective.

Authors:  Bradley D Shields; Alan J Tackett; Sara C Shalin
Journal:  Glob Dermatol       Date:  2016-06-20

Review 6.  Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects.

Authors:  Dekker C Deacon; Eric A Smith; Robert L Judson-Torres
Journal:  Front Med (Lausanne)       Date:  2021-04-16

Review 7.  Role of Biomarkers in the Integrated Management of Melanoma.

Authors:  Piyu Parth Naik
Journal:  Dis Markers       Date:  2021-12-30       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.